Evidence map›Paper›PMID 40956046›Full record

ArticleEpilepsia2025

Early seizure freedom with [

Roberta Rudà, Francesco Bruno, Alessia Pellerino, Edoardo Pronello, Michela Zotta, Silvia Morbelli

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Roberta RudàDivision of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-9134-1537
Francesco BrunoDivision of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-8087-5293
Alessia PellerinoDivision of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0003-3243-0059
Edoardo PronelloDivision of Neuro-Oncology, Department of Neuroscience "Rita Levi Montalcini", University and City of Health and Science Hospital, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0002-8680-0839
Michela ZottaDivision of Nuclear Medicine, Department of Medical Sciences, University and City of Health and Science Hospital, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0001-7376-7972
Silvia MorbelliDivision of Nuclear Medicine, Department of Medical Sciences, University and City of Health and Science Hospital, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0002-7833-6095

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vorasidenib, a dual isocitrate dehydrogenase 1/2 (IDH1/2) inhibitor, showed superior efficacy in prolonging progression-free survival and time to next intervention in IDH-mutant grade 2 gliomas. This case is part of an ongoing institutional study exploring the impact of vorasidenib on seizure control and the potential of [

Indexed as

Brain NeoplasmsIsocitrate DehydrogenaseOligodendrogliomaPositron-Emission TomographySeizuresTriazinesDihydroxyphenylalanineHumansMaleMiddle AgedDihydroxyphenylalaninefluorodopa F 18Isocitrate DehydrogenaseTriazinesamino acid PETF‐DOPA PETseizuresvorasidenib

Identifiers

PMID40956046
PMCPMC12605814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.